Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer

被引：0
|
作者：
Heller, Simon
Sugawara, Tatsuo
Nevedomskaya, Ekaterina
Baumgart, Simon J.
Nguyen, Holly
Corey, Eva
Bohme, Annika
von Ahsen, Oliver
Politz, Oliver
Haendler, Bernard
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 11期
关键词：
D O I：
10.1158/1538-7445.PRCA2023-B065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B065
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models
    Rossetti, Stefano
    Broege, Aaron
    Sen, Adrish
    Khan, Salmaan
    MacNeil, Ian
    Molden, Jhomary
    Gorbatchevsky, Igor
    Sullivan, Brian F.
    Laing, Lance
    CANCER RESEARCH, 2024, 84 (09)
  • [2] High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
    Marques, Rute B.
    Aghai, Ashraf
    de Ridder, Corrina M. A.
    Stuurman, Debra
    Hoeben, Sander
    Boer, Agnes
    Ellston, Rebecca P.
    Barry, Simon T.
    Davies, Barry R.
    Trapman, Jan
    van Weerden, Wytske M.
    EUROPEAN UROLOGY, 2015, 67 (06) : 1177 - 1185
  • [3] Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
    Roudsari, Nazanin Momeni
    Lashgari, Naser-Aldin
    Momtaz, Saeideh
    Abaft, Shaghayegh
    Jamali, Fatemeh
    Safaiepour, Pardis
    Narimisa, Kiyana
    Jackson, Gloria
    Bishayee, Anusha
    Rezaei, Nima
    Abdolghaffari, Amir Hossein
    Bishayee, Anupam
    PHARMACEUTICS, 2021, 13 (08)
  • [4] Combination of the androgen receptor inhibitor darolutamide and the PI3K inhibitor copanlisib leads to improved anti-tumor efficacy and apoptosis in prostate cancer models
    Sugawara, Tatsuo
    NGuyen, Holly
    Corey, Eva
    Nevedomskaya, Ekaterina
    Politz, Oliver
    Mumberg, Dominik
    Haendler, Bernard
    CANCER RESEARCH, 2022, 82 (12)
  • [5] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [6] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [7] Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis
    Sugawara, Tatsuo
    Nevedomskaya, Ekaterina
    Heller, Simon
    Boehme, Annika
    Lesche, Ralf
    von Ahsen, Oliver
    Gruenewald, Sylvia
    Nguyen, Holly M.
    Corey, Eva
    Baumgart, Simon J.
    Georgi, Victoria
    Puetter, Vera
    Fernandez-Montalvan, Amaury
    Vasta, James D.
    Robers, Matthew B.
    Politz, Oliver
    Mumberg, Dominik
    Haendler, Bernard
    MOLECULAR ONCOLOGY, 2024, 18 (03) : 726 - 742
  • [8] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [9] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [10] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
12345